Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-VASCOR: Allopurinol for Cardiovascular Risk
NCT05943821Phase 3Recruiting
- Sponsor
- Poznan University of Medical Sciences
- Start
- Sep 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular diseases (CVD) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Event at 5 years. Started Sep 2023; status: recruiting.
02
Drugs
allopurinol
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT05943821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943821.